Focused On-demand Library for Potassium voltage-gated channel subfamily H member 5

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8NCM2

UPID:
KCNH5_HUMAN

ALTERNATIVE NAMES:
Ether-a-go-go potassium channel 2; Voltage-gated potassium channel subunit Kv10.2

ALTERNATIVE UPACC:
Q8NCM2; C9JP98

BACKGROUND:
The protein known as Potassium voltage-gated channel subfamily H member 5, with alternative names Ether-a-go-go potassium channel 2 and Voltage-gated potassium channel subunit Kv10.2, is integral to the function of voltage-gated potassium channels. It is responsible for generating a non-inactivating outward rectifying current, crucial for maintaining the cell's electrical stability. The modulation of this protein's activity by cAMP and its subunit assembly highlights its significance in cellular signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Potassium voltage-gated channel subfamily H member 5 unveils potential avenues for therapeutic intervention. Given its central role in cellular electrophysiology, targeting this protein could lead to innovative treatments for conditions stemming from electrical imbalances in cells.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.